Integrating network pharmacology and experimental validation to explore the mechanisms of luteolin in alleviating fumonisin B1-induced intestinal inflammatory injury
Copyright © 2023 Elsevier Ltd. All rights reserved..
Contamination with fumonisin B1 (FB1) represents a global health problem. FB1 exposure may also trigger intestinal injury by activating inflammatory responses, leading to a reduction in production performance and economic benefits. However, the mechanism of FB1-induced intestinal inflammatory injury is still unclear. At the same time, it is urgent to develop antibiotic alternatives and therapeutic targets to alleviate antibiotic resistance and to ensure effective treatment of intestinal inflammatory injury. We combined network pharmacology and in vitro experiments to explore the core therapeutic targets and potential mechanism of luteolin in FB1-induced intestinal inflammatory injury. Network pharmacology and molecular docking revealed that nuclear factor kappa B (NF-κB) p65, extracellular signal-regulated kinase (ERK), interleukin 6 (IL-6) and IL-1β are the important targets, and the NF-κB and ERK signalling pathways are critical in FB1-induced intestinal inflammatory injury. Besides, in vitro experiments further demonstrated that luteolin can inhibit FB1-induced intestinal inflammatory injury by inhibiting activation of the NF-κB and ERK signalling pathways and reducing the expression of IL-6 and IL-1β in IPEC-J2 cells. We have comprehensively illustrated the potential targets and molecular mechanism by which luteolin can alleviate FB1-induced intestinal inflammatory injury. Luteolin may be an effective antibiotic alternative to prevent intestinal inflammatory injury.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:237 |
|---|---|
| Enthalten in: |
Toxicon : official journal of the International Society on Toxinology - 237(2023) vom: 27. Jan., Seite 107531 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wen, Defeng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3ZZM97XZ32 |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.toxicon.2023.107531 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365042382 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365042382 | ||
| 003 | DE-627 | ||
| 005 | 20231227140935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.toxicon.2023.107531 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM365042382 | ||
| 035 | |a (NLM)38013056 | ||
| 035 | |a (PII)S0041-0101(23)00342-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wen, Defeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrating network pharmacology and experimental validation to explore the mechanisms of luteolin in alleviating fumonisin B1-induced intestinal inflammatory injury |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Contamination with fumonisin B1 (FB1) represents a global health problem. FB1 exposure may also trigger intestinal injury by activating inflammatory responses, leading to a reduction in production performance and economic benefits. However, the mechanism of FB1-induced intestinal inflammatory injury is still unclear. At the same time, it is urgent to develop antibiotic alternatives and therapeutic targets to alleviate antibiotic resistance and to ensure effective treatment of intestinal inflammatory injury. We combined network pharmacology and in vitro experiments to explore the core therapeutic targets and potential mechanism of luteolin in FB1-induced intestinal inflammatory injury. Network pharmacology and molecular docking revealed that nuclear factor kappa B (NF-κB) p65, extracellular signal-regulated kinase (ERK), interleukin 6 (IL-6) and IL-1β are the important targets, and the NF-κB and ERK signalling pathways are critical in FB1-induced intestinal inflammatory injury. Besides, in vitro experiments further demonstrated that luteolin can inhibit FB1-induced intestinal inflammatory injury by inhibiting activation of the NF-κB and ERK signalling pathways and reducing the expression of IL-6 and IL-1β in IPEC-J2 cells. We have comprehensively illustrated the potential targets and molecular mechanism by which luteolin can alleviate FB1-induced intestinal inflammatory injury. Luteolin may be an effective antibiotic alternative to prevent intestinal inflammatory injury | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fumonisin B1 | |
| 650 | 4 | |a Intestinal inflammatory injury | |
| 650 | 4 | |a Luteolin | |
| 650 | 4 | |a Network pharmacology | |
| 650 | 4 | |a Therapeutic target | |
| 650 | 7 | |a fumonisin B1 |2 NLM | |
| 650 | 7 | |a 3ZZM97XZ32 |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Luteolin |2 NLM | |
| 650 | 7 | |a KUX1ZNC9J2 |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Han, Wantong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Quan |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Guanhui |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Mengling |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Pu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zhongyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Shulin |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Qirong |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Yinsheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Toxicon : official journal of the International Society on Toxinology |d 1964 |g 237(2023) vom: 27. Jan., Seite 107531 |w (DE-627)NLM00002371X |x 1879-3150 |7 nnns |
| 773 | 1 | 8 | |g volume:237 |g year:2023 |g day:27 |g month:01 |g pages:107531 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.toxicon.2023.107531 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 237 |j 2023 |b 27 |c 01 |h 107531 | ||